Quantbot Technologies LP increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 97.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,062 shares of the medical research company's stock after buying an additional 15,357 shares during the period. Quantbot Technologies LP's holdings in IQVIA were worth $6,104,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of IQVIA in the 4th quarter valued at about $236,120,000. FMR LLC lifted its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Finally, KBC Group NV lifted its position in shares of IQVIA by 68.5% during the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company's stock valued at $121,109,000 after acquiring an additional 250,458 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.
IQVIA Stock Performance
Shares of NYSE IQV traded down $5.04 during midday trading on Tuesday, reaching $181.07. The company's stock had a trading volume of 1,566,007 shares, compared to its average volume of 1,242,649. The stock has a market capitalization of $31.93 billion, a P/E ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a 50 day moving average price of $194.24 and a 200-day moving average price of $207.29. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $253.84.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Analyst Ratings Changes
IQV has been the subject of several research analyst reports. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $249.05.
Check Out Our Latest Research Report on IQV
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
